2023-03-16 16:56:13 ET
- Armata Pharmaceuticals press release ( NYSE: ARMP ): Q4 GAAP EPS of -$0.29 misses by $0.01 .
- Revenue of $1.05M (+6.1% Y/Y) misses by $0.62M .
-
Loss from Operations. Loss from operations for the three months ended December 31, 2022, was $(10.3) million as compared to a loss from operations of approximately $(6.0) million for the comparable period in 2021.
-
Cash and Equivalents. As of December 31, 2022, Armata held approximately $14.9 million of unrestricted cash and cash equivalents, as compared to $10.3 million as of December 31, 2021.
-
As of March 13, 2023, there were approximately 36.1 million shares of common stock outstanding.
For further details see:
Armata Pharmaceuticals GAAP EPS of -$0.29 misses by $0.01, revenue of $1.05M misses by $0.62M